Xyz historical perspective: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Protected "Xyz historical perspective" ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(11 intermediate revisions by 6 users not shown)
Line 2: Line 2:
{{xyz}}
{{xyz}}


{{CMG}}; {{AE}}  
{{CMG}}; {{AE}}


==Overview==
==Overview==
==Historical Perspective==
==Historical Perspective==


===Discovery===
===Discovery===
*In 1871, Bilroth, a Prussian-born Austrian surgeon, was the first to described a case of Non- Hodgkin lymphoma, and coined the term malignant lymphoma.
* There is limited information about the historical perspective of [disease name].
*In 1864, Virchow , a German physician , described lymph node enlargement not related to leukemia as lymphosarcoma a subdivision of aleukimic type of lukemias.
OR
*In 1865, Cohnheim, a German-Jewish physician , used the term pseudolukemia to describe all common lymphadenopathy and splenomegaly. <ref {{cite book | last = Pollock | first = Raphael | title = Advanced therapy in surgical oncology | publisher = BC Decker Inc | location = Hamilton, Ontario Lewiston, NY | year = 2008 | isbn = 9781550091267 }}</ref>
*[Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event].
*In 1958, [[Denis Parsons Burkitt]], an Irish [[surgeon]], first discovered Burkitt's lymphoma while working in Africa.<ref name="pmid13628987">{{cite journal |author=Burkitt D |title=A sarcoma involving the jaws in African children |journal=The British journal of surgery |volume=46 |issue=197 |pages=218–23 |year=1958 |pmid=13628987|doi=10.1002/bjs.18004619704}}</ref>
 
*In 1925, Follicular lymphoma was described by Brill and Symmers independently .{{cite journal |vauthors=van Besien K, Schouten H |title=Follicular lymphoma: a historical overview |journal=Leuk. Lymphoma |volume=48 |issue=2 |pages=232–43 |date=February 2007 |pmid=17325883 |doi=10.1080/10428190601059746 |url=}}
*The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
*In 1956, Henry Rappaport and his colleagues proposed the Rappaport classification, based on cellular morphology, this became the first widely accepted classification of lymphomas.
*In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
*In 1966,  Armed Forces Institute of Pathology (AFIP) modified the the Rappaport classification in the"Tumors of the Hematopoietic System".  
*In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].
*In 1982,  National Cancer Institute introduced the Working Formulation, an amalgamation translating all previous classifications, which defined three grades of non-Hodgkin lymphoma.<ref name="BennettFarrer-Brown1974">{{cite journal|last1=Bennett|first1=MichaelH.|last2=Farrer-Brown|first2=Geoffrey|last3=Henry|first3=Kristin|last4=Jelliffe|first4=A.M.|last5=Gerard-Marchant|first5=R.|last6=Hamlin|first6=Iris|last7=Lennert|first7=K.|last8=Rilke|first8=F.|last9=Stansfeld|first9=A.G.|last10=Van Unnik|first10=J.A.M.|title=CLASSIFICATION OF NON-HODGKIN'S LYMPHOMAS|journal=The Lancet|volume=304|issue=7877|year=1974|pages=405–408|issn=01406736|doi=10.1016/S0140-6736(74)91786-3}}</ref>
*In 1992, Banks first coined the term [[Mantle Cell Lymphoma|mantle cell lymphoma]] (MCL).<ref name="pmid1530105">{{cite journal| author=Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K et al.| title=Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. | journal=Am J Surg Pathol | year= 1992 | volume= 16 | issue= 7 | pages= 637-40 | pmid=1530105 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1530105  }} </ref>
*In 1994, the Revised European-American Classification of Lymphoid Neoplasms (REAL) classified non Hodgkin's lymphoma, based on immunologic, genetic and clinical characteristics of the disorders in addition to histopathologic characteristics of the tumor cells.


==Landmark Events in the Development of Treatment Strategies==
===Landmark Events in the Development of Treatment Strategies===
*In 1997, FDA approved rituximab, to treat patients with B-cell non-Hodgkin lymphoma that did not responds to other treatments.<ref name="pmid11467356">{{cite journal |vauthors=Grillo-López AJ, White CA, Dallaire BK, Varns CL, Shen CD, Wei A, Leonard JE, McClure A, Weaver R, Cairelli S, Rosenberg J |title=Rituximab: the first monoclonal antibody approved for the treatment of lymphoma |journal=Curr Pharm Biotechnol |volume=1 |issue=1 |pages=1–9 |date=July 2000 |pmid=11467356 |doi= |url=}}</ref>


==Impact on Cultural History==
===Impact on Cultural History===


==Famous Cases==
===Famous Cases===
The following are a few famous cases of [[disease name]]:
The following are a few famous cases of [disease name]:


==References==
==References==
Line 33: Line 28:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category: (name of the system)]]

Latest revision as of 14:26, 22 November 2019

Xyz Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Xyz from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Xyz historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Xyz historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Xyz historical perspective

CDC on Xyz historical perspective

Xyz historical perspective in the news

Blogs on Xyz historical perspective

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Xyz historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Historical Perspective

Discovery

  • There is limited information about the historical perspective of [disease name].

OR

  • [Disease name] was first discovered by [name of scientist], a [nationality + occupation], in [year]/during/following [event].
  • The association between [important risk factor/cause] and [disease name] was made in/during [year/event].
  • In [year], [scientist] was the first to discover the association between [risk factor] and the development of [disease name].
  • In [year], [gene] mutations were first implicated in the pathogenesis of [disease name].

Landmark Events in the Development of Treatment Strategies

Impact on Cultural History

Famous Cases

The following are a few famous cases of [disease name]:

References

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Xyz_historical_perspective&oldid=1589920"